Peer-reviewedCC BY-NCBio-protocol
Immune-Complex-Based In Vitro Deubiquitination Assay
- 1Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada
- 2Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada
Related
- pSIM: A next generation in vitro mRNA potency assay.
- Circular RNA CD47 triggers the tumor progression and immunoregulation of non-small cell lung cancer via miR-889-3p/COPS5-mediated PD-L1 deubiquitination
- Genetic-multi-omics causal inference coupled with integrative in-vitro toxicology reveals immune-metabolite mediators for aortic aneurysm risk
- Addressing complex autofluorescence signatures in solid tissue samples to enhance full spectrum flow cytometry of non-immune cells
- Beyond Receptor-Proximal Uncoupling: EGFR-PKC Signaling and Arrestin Deubiquitination-Coupled Nuclear Trafficking in GPCR Signaling Regulation
BibTeX
@article{do2026immunecomplexbased,
title = {{Immune-Complex-Based In Vitro Deubiquitination Assay}},
author = {Florence Dô and Sylvain Meloche and Marc J. Servant},
journal = {Bio-protocol},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13652713},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Immune-Complex-Based In Vitro Deubiquitination Assay
AU - Florence Dô
AU - Sylvain Meloche
AU - Marc J. Servant
PY - 2026
DA - 2026/10/05
JO - Bio-protocol
UR - https://europepmc.org/article/PMC/PMC13652713
SN - 2331-8325
ER -